Marksans Pharma Faces Mixed Financial Signals Amidst Growth and Operational Challenges
Marksans Pharma has recently experienced an evaluation adjustment due to its financial and technical metrics. While net sales and profit after tax showed growth, concerns arose from low return on capital employed and inventory turnover. The technical indicators present a mixed outlook, reflecting the company's complex operational landscape.
Marksans Pharma, a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment that reflects changes in its financial and technical metrics. The company's financial performance for the quarter ending March 2025 has been characterized as flat, leading to a revision in its score. Notably, net sales for the first nine months reached Rs 2,032.23 crore, marking a growth of 21.16%. Additionally, the profit after tax for the latest six months stood at Rs 195.11 crore, with a growth rate of 20.79%. However, certain indicators have raised concerns. The return on capital employed (ROCE) has reached a low of 18.49%, and the inventory turnover ratio is at its lowest point of 3.10 times. These factors contribute to the overall assessment of the company's financial health.
On the technical side, the trend has shifted to a sideways movement, indicating a lack of clear price momentum. The technical indicators present a mixed picture, with some showing mildly bullish signals while others reflect a bearish stance.
Overall, the adjustments in evaluation for Marksans Pharma highlight a complex interplay of growth and challenges within its operational framework.
Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Most Read
